Key Details
Price
$90.90Annual ROE
8.59%Beta
0.50Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Oct 23, 2024Recent annual earnings:
Jan 31, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 06, 2003Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Boston Scientific's recent acquisition will enhance its range of interventional oncology products.
Boston Scientific (BSX) shared its earnings report 30 days ago. What can we expect for the stock moving forward?
Research shows that the stroke risk reduction device works as well as oral anticoagulants for patients with atrial fibrillation after a cardiac ablation. On November 16, 2024, Boston Scientific Corporation announced encouraging three-year results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.
Boston Scientific Corporation (NYSE:BSX) will be participating in the UBS Global Healthcare Conference on November 12, 2024, at 10:15 AM ET. The company representatives include Jonathan Monson, Senior Vice President of Investor Relations, and Nick Spadea-Anello, Vice President and General Manager of Interventional Cardiology. Danielle Antalffy from UBS will also be part of the conference call, welcoming everyone in the morning.
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included the "Kidney Stone Management Market Report and Forecast 2024-2032" in its collection. In 2023, the global kidney stone management market was valued at USD 1.80 billion. It is projected to grow at a rate of 5.20% annually from 2024 to 2032, reaching an estimated USD 2.84 billion by 2032.
Boston Scientific Corporation (NYSE: BSX) has announced that it will acquire Cortex, Inc., a company under Ajax Health, to enhance its electrophysiology offerings. This acquisition aims to improve the treatment options for complex atrial fibrillation. The agreement was made public on November 4, 2024, in Marlborough, Massachusetts.
Boston Scientific Corporation (NYSE:BSX) will hold a Business Update Earnings Conference Call on October 30, 2024, at 4:00 PM ET. The call will feature company representatives, including Jonathan Monson, Joseph Fitzgerald, Lance Bates, Janar Sathananthan, and Kenneth Stein. Please be aware that this event is being recorded.
No matter if you focus on value, growth, or momentum investing, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key benefits of the Zacks Premium research service.
BSX's Endoscopy division in MedSurg is benefiting from high global demand for its wide variety of gastrointestinal and pulmonary treatment solutions.
Boston Scientific, a company that makes medical devices, is expected to keep growing its profits over the next few years. This positive outlook is supported by its strong history, good profit margins, product pipeline, and smart use of capital. Although other analysts on Seeking Alpha have given it a Hold rating this year, I believe it deserves a Buy rating and anticipate a nearly 15% increase in its price over the next year.
FAQ
- What is the primary business of Boston Scientific?
- What is the ticker symbol for Boston Scientific?
- Does Boston Scientific pay dividends?
- What sector is Boston Scientific in?
- What industry is Boston Scientific in?
- What country is Boston Scientific based in?
- When did Boston Scientific go public?
- Is Boston Scientific in the S&P 500?
- Is Boston Scientific in the NASDAQ 100?
- Is Boston Scientific in the Dow Jones?
- When was Boston Scientific's last earnings report?
- When does Boston Scientific report earnings?
- Should I buy Boston Scientific stock now?